Cinnarizine Avexima influences smooth muscles of vessels, decreases their reaction to biogenic substances (adrenaline, noradrenaline, dopamine, angiotensin, vasopressin). It has a vasodilatory action (especially with respect to cerebral blood vessels) without any significant effects on arterial pressure.
It produces moderate antihistamine action, decreases the vestibular apparatus excitability, reduces sympathetic tone. The medicinal product improves the red blood cell membrane elasticity, their ability to deform, reduces blood viscosity. It increases muscles resistance to hypoxia.
Indications for use:
Cerebrovascular disorders: — dizziness, tinnitus, headache, impaired memory, reduced attention concentration — symptoms of cerebrovascular insufficiency; — vestibular disorders (including Meniere's disease: dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinth origin); - prophylaxis of kinetoses ("motion sickness" - sea and air sickness); - migraine (prevention of attacks).
In cerebrovascular insufficiency: 25 mg three times daily.
In peripheral circulatory disorders: 50-75 mg three times daily.
In vestibular disorders: 25 mg three times daily.
Maximal recommended dose should not exceed 225 mg (9 tablets) daily. The treatment course consists of several weeks to several months.
In kinetosis ("motion sickness"): - for adults - 25 mg half an hour before the trip (if required, repeat the dose of 25 mg after 6 hours), - for children over 5 years - ½ dose recommended for adults.
In case of hypersensitivity to the medicinal product, the treatment is started with a ½ dose with subsequent gradual increasing.
Shelf life
2 years. Do not use after the expiry date indicated on the packaging.
Manufacturer
LLC "Avexima Siberia"
THERE ARE CONTRAINDICATIONS. READ THE INSTRUCTION OR CONSULT A MEDICAL SPECIALIST BEFORE USE
